 reuters    u s  democratic senator claire mccaskill sought on tuesday details from the nation s top opioid drugmakers on their sales and marketing practices  as lawmakers step up efforts to tackle the country s deadly opioid crisis  the missouri senator s investigation comes amid an epidemic of opioid addiction  with  americans dying everyday as a result of overdose  according to the u s  centers for disease control and prevention   this epidemic is the direct result of a calculated sales and marketing strategy major opioid manufacturers have allegedly pursued over the past  years to expand their market share   mccaskill  the top democrat on the senate homeland security and governmental affairs committee  wrote in a letter to the drugmakers   bit ly   mccaskill asked johnson   johnson  mylan nv  purdue pharma  insys therapeutics inc and depomed inc for internal estimates of the risk of abuse  addiction and overdose of opioids  the companies are the top five u s  prescription opioid drugmakers by  sales  according to mccaskill s letter  depomed and purdue pharma said they were reviewing the letter and would respond accordingly  purdue also said its oxycontin painkiller made up just  percent of the u s  opioid analgesic prescription market  johnson   johnson said it had received the letter and would address the senator s request   we believe that we have acted appropriately  responsibly and in the best interests of patients regarding our opioid pain medications   said jessica castles smith  a spokeswoman for johnson   johnson unit janssen  mylan said it is committed to helping find solutions to the issue of opioid abuse and misuse   we welcome the senator s interest in this important matter and we share her concerns regarding the misuse of prescription opioids   a mylan spokeswoman told reuters in an email  